LinkedIn Profile

Access Xcovery historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal GICS Sector GICS Industry
private:xcovery 647976 Feb 14th, 2020 12:00AM Xcovery 639 11.00 Open Biotechnology Feb 14th, 2020 03:40PM Feb 14th, 2020 03:40PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 12th, 2020 12:00AM Xcovery 638 11.00 Open Biotechnology Feb 12th, 2020 04:46PM Feb 12th, 2020 04:46PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 11th, 2020 12:00AM Xcovery 638 11.00 Open Biotechnology Feb 10th, 2020 07:51PM Feb 11th, 2020 01:10PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 10th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 9th, 2020 08:09PM Feb 9th, 2020 08:09PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 9th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 9th, 2020 06:09PM Feb 9th, 2020 06:09PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 8th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 8th, 2020 06:33PM Feb 8th, 2020 06:33PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 7th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 7th, 2020 04:30PM Feb 7th, 2020 04:30PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 6th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 6th, 2020 05:12PM Feb 6th, 2020 05:12PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 5th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 5th, 2020 05:41PM Feb 5th, 2020 05:41PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services
private:xcovery 647976 Feb 4th, 2020 12:00AM Xcovery 637 11.00 Open Biotechnology Feb 4th, 2020 03:04PM Feb 4th, 2020 03:04PM Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases. Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com Open Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research Open 11780 US Hwy 1, Suite 202 Palm Beach Gardens Florida US 33408 Health Care Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.